| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Kaposi’s sarcoma-associated herpesvirus (KSHV; also known as HHV-8) is a rhadinovirus of the gamma-herpesvirus subfamily and the eighth human herpesvirus to be discovered. KSHV is the causative agent of Kaposi’s sarcoma and acquired immunodeficiency syndrome (AIDS)-related lymphoproliferative disorders, such as plasmablastic variant multicentric Castleman’s disease and primary effusion lymphoma (PEL). In this study, we demonstrated that KSHV-encoded the latency associated nuclear antigen (LANA) is stabilized by de-ubiquitinating enzyme (HSUSP), and enhances the replication and the maintenance of viral DNA. Forthermore, we found that the pyrrolidinium fullerene (C60) and an allyl sulfide have the antitumor activity against PEL cells, suggesting that fullerene and allyl sulfide may represent a novel therapy for the treatment of PEL.
|
